Challenges in the translation and commercialization of cell therapies

Abstract

BackgroundCell therapies are an emerging form of healthcare that offer significant potential to improve the practice of medicine and provide benefits to patients who currently have limited or no treatment options. Ideally, these innovative therapies can complement existing small molecule, biologic and device approaches, forming a so-called fourth pillar of medicine and allowing clinicians to identify the best treatment approach for each patient. Despite this potential, cell therapies are substantially more complex than small molecule or biologic interventions. This complexity poses challenges for scientists and firms developing cell therapies and regulators seeking to oversee this growing area of medicine.ResultsIn this project, we retrospectively examined the development of seven cell therapies – including three autologous interventions and four allogeneic interventions – with the aim of identifying common challenges hindering attempts to bring new cell therapies to market. We complemented this analysis with a series of qualitative interviews with experts in various aspects of cell therapy. Through our analysis, which included review of extant literature collected from company documents, newspapers, journals, analyst reports and similar sources, and analysis of the qualitative interviews, we identified several common challenges that cell therapy firms must address in both the pre- and post-market stages. Key pre-market challenges included identifying and maintaining stable funding to see firms through lengthy developmental timelines and uncertain regulatory processes. These challenges are not unique to cell therapies, of course, but the novelty of cell-based interventions complicates these efforts compared to small molecule or biologic approaches. The atypical nature of cell therapies also led to post-market difficulties, including challenges navigating the reimbursement process and convincing providers to change their treatment approaches. In addition, scaling up production, distributing cell therapies and managing the costs of production were challenges that started pre-market and continued into the post-market phase.ConclusionsOur analysis highlights several interrelated challenges hindering the development of cell therapies. Identifying strategies to address these challenges may accelerate the development and increase the impact of novel cell therapies.

Advances in Skin Regeneration Using Tissue Engineering

“…Other commercial skin substitutes such as Apligraf TM , Celaderm TM , Dermagraft TM , Trancyte TM , and OrCel TM (Figure 3), are constructed from sheets of cells derived from neonatal (allogenic) foreskin [19,63,92,93]. TransCyte™ has similar configuration to Biobrane ® and consists of a nylon mesh seeded with fibroblasts cultured from neonatal human foreskin.…”

Repairing Injured Skin: Biologics, Skin Substitutes, and Scaffolds: Review

“…Company: Dremagraft, which is produced by Organogenesis Inc., Canton, MA, USA is sterile and derived from human dermal fibroblasts generated by the culture of neonatal dermal fibroblasts onto a polyglactin mesh scaffold (38)(39)(40).…”

Global Regulatory Differences for Gene‐ and Cell‐Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation

“…Market access is a second challenge for developers after regulatory approval. The one approved GCT in Canada was never marketed, and the developer did not reach approval in other jurisdictions . Currently, four EU‐marketed GCTs have been withdrawn after approval due to market failure.…”